Clinical trial · Interventional
Positron Emission Tomography in Prostate Cancer
NCT00121212CI-TRIAL-00019663completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Diagnostic procedures, such as positron emission tomography using carbon-11 acetate, may help find metastases from prostate cancer and may help predict whether prostate cancer will come back after treatment. PURPOSE: This clinical trial is studying how well positron emission tomography using carbon-11 acetate works in finding metastases and predicting recurrence in patients with prostate cancer who are at risk for recurrence after treatment.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| carbon-11 acetate PET scan | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- ACTIVE_COMPARATOR
- label
- Surgery - Negative PET scan
- description
- If patient is candidate for surgery with curative intent or staging lymphadenectomy, he will be enrolled in the study. If patient's PET scan is negative, the patient will receive the curative therapy and be followed for recurrence.
- interventionNames
- Procedure: carbon-11 acetate PET scan
- type
- EXPERIMENTAL
- label
- Surgery - Positive PET scan
- description
- If patient is candidate for surgery with curative intent or staging lymphadenectomy, he will be enrolled in the study. If patient's PET scan is positive, the patient will receive the curative therapy and be followed for recurrence or receive alternative therapy.
- interventionNames
- Procedure: carbon-11 acetate PET scan
- type
- ACTIVE_COMPARATOR
Eligibility
Eligibility (as posted)
- Sex
- Male
Show eligibility criteria text
Inclusion Criteria * Newly diagnosed prostate cancer * Has completed conventional staging examinations, including biopsy with Gleason score, CT scan of the abdomen and pelvis, and whole-body bone scintigraphy AND conventional staging examinations negative * Candidate for curative radical prostatectomy OR curative radiotherapy OR staging lymphadenectomy prior to surgery * Deemed to be at medium or high risk for recurrence after initial curative treatment, as defined by 1 of the following criteria: * Gleason score 7 AND prostate-specific antigen (PSA) 10-20 ng/mL * Gleason score ≥ 8 AND PSA \< 10 ng/mL * Gleason score ≥ 8 AND PSA \> 10 ng/mL * Any Gleason score AND PSA \> 20 ng/mL Exclusion Therapy: * Not a candidate for treatment by surgery or radiation therapy with curative intent * Inability to give informed consent * Patients with other invasive malignancies, with the exception of non-melanoma skin cancer, who had (or have) any evidence of other cancer present within the last 5 years
References
Publications (0)
Data not yet available
No reference posted for this study.